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OBJECTIVE — The negative results of two randomized controlled trials (RCTs) have chal-
lenged current guideline recommendations for using aspirin for primary prevention of cardio-
vascular events among patients with diabetes. We therefore sought to determine if the effect of
aspirin for primary prevention of cardiovascular events and mortality differs between patients
with and without diabetes.
RESEARCH DESIGN AND METHODS — We conducted a systematic search of
MEDLINE,EMBASE,CochraneLibrary,WebofScience,andScopussincetheirinceptionsuntil
November 2008 for RCTs of aspirin for primary prevention of cardiovascular events. Blinded
pairsofreviewersevaluatedstudiesandextracteddata.Random-effectsmeta-analysisandBayes-
ian logistic regression were used to estimate the ratios of relative risks (RRs) of outcomes of
interest among patients with and without diabetes. A 95% CI that crosses 1.00 indicates that the
effect of aspirin does not differ between patients with and without diabetes.
RESULTS — NineRCTswithmoderatetohighmethodologicalqualitycontributeddatatothe
analyses. The ratios of RRs comparing the beneﬁt of aspirin among patients with diabetes
compared with patients without diabetes for mortality, myocardial infarction, and ischemic
stroke were 1.12 (95% CI 0.92–1.35), 1.19 (0.82–1.17), and 0.70 (0.25–1.97), respectively.
CONCLUSIONS — Whereas estimates of beneﬁt among patients with diabetes remain im-
precise, our analysis suggests that the relative beneﬁt of aspirin is similar in patients with and
without diabetes.
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C
ardiovascular events including myo-
cardial infarction and ischemic
strokearetheleadingcausesofmor-
bidity and mortality in patients with dia-
betes, and the population burden of
cardiovascular disease attributed to dia-
betes appears to be increasing (1). Several
guidelines, including those of the Ameri-
can Diabetes Association, recommend as-
pirin for the primary prevention of
cardiovascular events in patients with di-
abetes(2,3).Giventhattrialsofaspirinfor
primary prevention have enrolled too few
patients with diabetes, guideline panels
haveappliedindirectevidencefromother
high-risk groups to formulate this recom-
mendation (4). In contrast, other guide-
lines such as those of the European
Society of Cardiology and the European
Association for the Study of Diabetes (5)
and the most recent U.S. Preventive Ser-
vices Task Force (6) provide no speciﬁc
recommendationsregardingtheuseofas-
pirin in patients with diabetes.
The best available estimate of the ef-
fectofaspirincomesfromthemostrecent
study from the Antithrombotic Trialists’
Collaborative, an individual-level meta-
analysis of randomized controlled trials
(RCTs) that reported a 12% reduction in
the rate ratio of serious vascular events in
patients with diabetes randomized to as-
pirin prophylaxis, although this ﬁnding
was not statistically signiﬁcant (rate ratio
0.88, 95% CI 0.67–1.15) (7). However,
this meta-analysis did not include data
from the Early Treatment Diabetic Reti-
nopathy Study (ETDRS) (8) nor two re-
cent primary prevention RCTs, the
Japanese Primary Prevention of Athero-
sclerosis With Aspirin for Diabetes
(JPAD) (9) and the Prevention of Progres-
sionofArterialDiseaseandDiabetes(PO-
PADAD) (10) studies. Results from both
JPAD and POPADAD, however, were im-
precise and unable to exclude a reduction
in the risk for their composite end points
of up to 42 and 24%, respectively.
We, therefore, set out to conduct a
systematic review of RCTs of aspirin for
primary prevention in patients with dia-
betes to 1) estimate the efﬁcacy of aspirin
for the primary prevention of cardiovas-
culareventsamongpatientswithdiabetes
and 2) estimate the extent to which the
effect of aspirin differs in patients with
and without diabetes.
RESEARCH DESIGN AND
METHODS— The report of this pro-
tocol-driven systematic review adheres to
the Quality of Reporting of Meta-analyses
(QUOROM) standards for reporting sys-
tematicreviewsofrandomizedclinicaltri-
als (11).
Eligibility criteria
Eligible studies were RCTs that enrolled
patientswithdiabeteswithoutapriorhis-
tory of myocardial infarction or stroke
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dosage.
Study identiﬁcation and retrieval
An expert reference librarian designed
andconductedtheelectronicsearchstrat-
egy. Our systematic search included
MEDLINE, EMBASE, Cochrane Library,
Web of Science, and Scopus, since their
inceptions until November 2008. We used
database-speciﬁccontrolledlanguageand
terms that describe the key concepts: as-
pirin, diabetes, cardiovascular events,
prevention, and randomized trials. We
also reviewed the reference sections of
identiﬁed reviews, published guidelines,
and published manuscripts known to the
authors. Study inclusion was not limited
by publication status or language.
Pairs of reviewers, working indepen-
dently and in duplicate, identiﬁed poten-
tially eligible records for full-text retrieval
from the titles and abstracts. Records in
which the reviewers disagreed were also
retrieved in full text. The reviewers as-
sessed the retrieved full-text articles for
eligibility. An independent reviewer re-
solved disagreements.
Outcomes
The outcomes of interest were ischemic
stroke, myocardial infarction, and all-cause
mortality.
Data abstraction
Two reviewers extracted the following
datafromeacheligiblearticle:description
of study participants, study characteris-
tics, and outcome data.
Quality assessment
Independent reviewers working in du-
plicate determined the extent to which
trials reported concealment of alloca-
tion; blinding of patients, providers,
and outcome assessors; and the extent
of loss to follow-up.
Author contact
We contacted the corresponding and/or
ﬁrst author of each eligible article identiﬁed
in the screening process by e-mail to con-
ﬁrm data extraction and quality assessment
and to request missing information.
Prevention of cardiovascular events
with aspirin
We used the  statistic to quantify chance-
adjusted agreement between reviewers
for article selection. Random-effects
meta-analyses estimated the pooled treat-
menteffects(relativerisks[RRs]andtheir
95% CIs) of aspirin in preventing cardio-
vascular events and all-cause death in pa-
tients with diabetes and without diabetes.
TheI
2statisticestimatedthepercentageof
inconsistency across studies that was due
to heterogeneity rather than chance or
random error (12).
Given that subjects included in the
Antiphospholipid Antibody–Acetylsali-
cylicAcid(APLASA)studywerereceiving
aspirin for antiphospholipid antibody
syndrome and had a short duration of
follow-upandthatasmallnumberofsub-
jectsinETDRShadsufferedapriorstroke
or myocardial infarction, we conducted
sensitivity analysis to determine whether
the exclusion of these studies affected the
conclusions of this review.
Interaction between the effect of
aspirin and diabetes status
We implemented three methods to de-
termine whether a difference exists in
aspirin effect in patients with and with-
out diabetes. First, we estimated the ra-
tio of RRs and its 95% CI using the
method of Altman and Bland (13). This
estimate compares the pooled RRs
across subgroups of patients with dia-
betes and without across trials. Pooled
estimates that exclude a ratio of 1 pro-
vide evidence of an aspirin-diabetes in-
teraction. Second, we estimated the
ratioofRRscomparingtheaspirineffect
in patients with and without diabetes
within trials and then pooled these ra-
tios. Again, pooled estimates that ex-
clude a ratio of RRs of 1 indicate a
statistically signiﬁcant difference in the
treatment effect of aspirin in patients
with and without diabetes. We used
Comprehensive Meta-Analysis version
2 software (Biostat, Englewood, NJ) and
StatsDirect 2.5.4 (StatsDirect, Cheshire,
U.K.) to conduct these analyses. Finally,
we conducted a Bayesian random-effects
logisticregressionwithaspirinuseanddi-
abetes status as the main effect factors,
and an interaction term of these two was
also applied to the included trials. A 95%
credible interval of the regression coefﬁ-
cient of the interaction term that excludes
0 indicates that the effect of aspirin is dif-
ferent in patients with and without diabe-
tes. This analysis was carried out using
WinBUGS1.4(MedicalResearchCouncil
andImperialCollegeofScience,Technol-
ogy and Medicine, U.K.) with noninfor-
mative prior distributions and three
parallel Markov Chain Monte Carlo
chains with overdispersed initials. The
Brooks-Gelman-Rubin (14) convergence
diagnostic was applied to examine the con-
vergence of the Markov Chain Monte Carlo
samplers. Statistical inferences were
then drawn based on the resulting pos-
terior distributions of parameters of in-
terest. For RCTs with zero events in one
study arm, we used a continuity correc-
tion factor of 0.5 and conducted sensi-
tivity analysis using the treatment arm
method to test whether the choice of
statistical methods affected study con-
clusions (15).
RESULTS
Search results
Figure 1 describes the process of study
selection that yielded eight eligible RCTs
Figure 1—Flow diagram of the process of study selection. CV, cardiovascular.
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Langhennig et al. (16) did not report any
events of interest and therefore was not
included in the main analysis. Table 1 de-
scribes the included studies showing im-
portantdifferencesinthestudies.Authors
from 50% of eligible RCTs responded to
our data requests (9,17–19).
Methodological quality
Table2showsthemethodologicalquality
of the included RCTs. The  statistic for
quality assessment identiﬁed through the
screening process was 0.70 (range 0.64–
0.87). Overall, trials had high method-
ological quality, with more than half of
them concealing allocation and blinding
patients and caregivers, most reporting
minimal loss to follow-up, and only one
was stopped earlier than planned because
ofﬁndingsigniﬁcantbeneﬁtduringanin-
terim analysis.
Prevention of cardiovascular events
with aspirin
Figure 2A–C demonstrates the pooled
RRs and 95% CI for the effect of aspirin
versus control on death, myocardial in-
farction, and ischemic stroke, respec-
tively, stratiﬁed by diabetes status. The
estimates of RR and 95% CI among all
patients regardless of diabetes status for
the outcomes of mortality, myocardial
infarction, and ischemic stroke were
0.93 (95% CI 0.85–1.03; I
2 0%), 0.79
(0.66–0.95; I
2 63%), and 0.73 (0.43–
1.22; I
2 39%), respectively. Estimates
among patients with diabetes were 0.97
(0.87–1.08; I
2 0%), 0.86 (0.67–1.11; I
2
53%), and 0.62 (0.31–1.24; I
2 67%),
respectively. The corresponding esti-
mates among patients without diabetes
were 0.87 (0.75–1.02; I
2 0%), 0.72
(0.55–0.95; I
2 70%), and 0.89 (0.41–
1.94; I
2 0%), respectively.
Table 1—Description of included trials
Patient population
Inclusion
age
(years)
Participants
(% female)
Participants
with
diabetes
(%)
Aspirin
treatment Control
Average
study
duration
(years)
Diabetes
subgroup
outcomes
reported
APLASA (18) Persistently antiphospholipid
antibody–positive patients
18 98 (90) 6 (6) 81 mg daily Placebo 2.3 Mortality, MI,
stroke
Hypertension
Optimal
Treatment
(19,27) Patients with hypertension 50–80 18,790 (47) 1,501 (8) 75 mg daily Placebo 3.8 Mortality, MI
ETDRS (8) Patients with diabetes and
diabetic retinopathy
18–70 3,711 (44) 3,711 (100) 650 mg daily Placebo 5.0 Mortality, MI
JPAD (9) Patients with type 2 diabetes 30–85 2,539 (45) 2,539 (100) 81 or 100 mg
daily
Open label 4.4 Mortality, MI,
stroke
Physicians’ Health
Study (28) Healthy male physicians 40 22,071 (0) 533 (2) 325 mg every
other day
Placebo 5.0 MI
POPADAD (24) Patients with diabetes,
asymptomatic PAD, and
no symptomatic CVDs
40 1,276 (56) 1,276 (100) 100 mg daily Placebo 6.7 Mortality, MI
Primary Prevention
Project (29) Patients without history of
CVD
50 1,031 (52) 1,031 (100) 100 mg daily* Open label 3.6 MI, stroke
Women’s Health
Study (17) Female health care
professionals without CVD
45 39,876 (100) 1,037 (3) 100 mg every
other day†
Placebo 10.1 MI, stroke
CVD, cardiovascular disease; MI, myocardial infarction; PAD, peripheral arterial disease. *Also randomized to vitamin E. †Also randomized to -carotene.
Table 2—Risk of bias in included trials
Blinding:
caregivers
Blinding:
patients
Blinding:
outcome
assessors
Blinding:
data
collectors
Allocation
concealment
Lost to
follow-up
Funding
source
Trial
stopped
early
APLASA Yes Yes Yes Yes Yes 5% FP No
ETDRS Yes Yes Yes Yes Yes 10% NFP No
Hypertension Optimal Treatment Yes Yes Yes No Yes 3% FP No
JPAD No No Yes Yes Yes 8% NFP No
Physicians’ Health Study Yes Yes Yes NR/NC NR/NC 1% FP No
POPADAD Yes Yes Yes Yes Yes 1% FP No
Primary Prevention Project No No NR No Yes NR/NC FP Yes
Women’s Health Study Yes Yes Yes No NR/NC NR/NC FP No
FP, includes for-proﬁt sources; NFP, does not include for-proﬁt sources; NR/NC, proﬁt status not reported or not clear.
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aspirin and diabetes status
Table 3 describes the results of between-
study subgroup analysis, within-study sub-
group analyses, and Bayesian random-
effects regression analyses. All three
methods yielded nonsigniﬁcant ratios of
RRofaspirininpatientswithandwithout
diabetes across all outcomes examined.
The choice of continuity correction
method for RCTs with zero events in one
arm did not substantially affect inferences.
Figure 2—Forest plots for mortality, myocardial infarction, and ischemic stroke. Forest plots of random-effects meta-analysis for pooled RRs of
mortality (A), myocardial infarction (B), and ischemic stroke (C). Results are presented for patients with and without diabetes and for all patients
combined. Squares and horizontal lines represent the point estimates and associated 95% CI. The diamonds represent the pooled RR, with the center
representing the point estimate and the width representing the associated 95% CI. ASA, aspirin; HOT, Hypertension Optimal Treatment; PHS,
Physicians’ Health Study; PPP, Primary Prevention Project; WHS, Women’s Health Study.
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Our conclusions were not signiﬁcantly
altered by the exclusion of the APLASA
(Pinteraction 0.28, 0.36, and 0.63 for mor-
tality, myocardial infarction, and isch-
emic stroke, respectively) or ETDRS trials
(Pinteraction 0.18, 0.62, and 0.48 for mor-
tality, myocardial infarction, and isch-
emic stroke, respectively).
CONCLUSIONS — Consistent with
prior studies (7,9,10), we found no sig-
niﬁcant beneﬁt of aspirin therapy for
the primary prevention of cardiovascu-
lareventsamongpatientswithdiabetes.
Even for the outcome of myocardial in-
farction,inwhichtheoverallriskreduc-
tion was statistically signiﬁcant, our
estimated risk reduction among pa-
tients with diabetes remained nonsig-
niﬁcant. However, our estimates were
imprecise and unable to exclude a treat-
ment beneﬁt of 13, 33, and 69% for the
outcomes of mortality, myocardial in-
farction, and ischemic stroke, respec-
tively.Usingabetween-studiesapproach,
a within-studies approach, and a Bayes-
ian analysis, we found evidence that the
effect of aspirin among patients with di-
abetes was not signiﬁcantly different
from patients without diabetes. Thus,
the data we present here provide impre-
cise evidence of beneﬁt from using as-
pirin in patients with diabetes without a
history of cardiovascular events; this
treatment effect does not differ signiﬁ-
cantly from that observed in patients
without diabetes.
Limitations and strengths
The main limitation of our study relates
to our use of published aggregate data
and lack of statistical power. The possi-
bility of publication bias cannot be ad-
equately assessed and corrected given
the small number of RCTs (20). Our
comprehensive literature search mini-
mized the risk of publication and re-
porting biases, although our author
response rate was relatively low and re-
sulted in less complete data. It is possi-
ble that other aspirin RCTs have
examined diabetes subgroups but have
not reported these results because of
lack of a signiﬁcant aspirin-diabetes in-
teraction. If this were to be the case,
their inclusion would likely strengthen
our conclusions. The small number of
included trials and the small number of
events within these trials reduced the
statistical power and therefore the pre-
cision of the estimates in our main anal-
ysis and in our tests for interaction
between aspirin effect and diabetes sta-
tus. Our analyses using multiple statis-
tical methods to examine the diabetes-
aspirin interaction and their consistent
results strengthen our conclusions.
While the use of composite end points
would have increased our statistical
power, we chose to pool individual end
points because the composite end
points in the included trials represent
outcomeswithlargegradientsinimpor-
tance to patients and in potential mag-
nitude of the effect of treatment across
component end points (21). We did not
examine the potential harm from aspi-
rin therapy such as gastrointestinal
bleeding, since these events in the small
population of patients with diabetes in-
cluded in RCTs are usually rare, leading
to imprecise estimates. Hence, evidence
about harm is better obtained from
larger studies that include patients
without diabetes.
Implications
Our inferences should be considered in
the context of proposed criteria to eval-
uate the validity of a subgroup effect
(22).Goodevidenceofavalidsubgroup
effect results from testing few a priori
hypotheses based on strong biological
rationale. The extent to which this is
true for the diabetes subgroup analyses
reported in the literature is unclear to
us. Our analyses, however, do not sup-
port other criteria for a valid subgroup
effect. We found that differences in as-
pirin treatment effect between patients
with and without diabetes, both between
and within RCTs, were inconsistent and
of small magnitude. Thus, the current
best evidence suggests that the efﬁcacy
of aspirin for the primary prevention of
cardiovascular events in patients with
diabetes is similar to that in patients
without diabetes.
The decision to use aspirin for pri-
mary prevention in individual patients
with diabetes remains a complex issue.
Ultimately, the decision to use aspirin
for an individual patient should con-
sider the advantages and disadvantages
of this preventive treatment given the
patient’s context and preferences. We
suggest ﬁrst estimating the 10-year risk
of coronary heart disease (23,24). Mul-
tiplying this estimate by 0.88 (12% rel-
ative risk reduction with the use of
aspirin based on data from the Anti-
thrombotic Trialists’ Collaborative [7])
would provide the revised 10-year risk
estimateforapatientusingaspirin.This
should be presented alongside the risk
of major gastrointestinal and extracra-
nial bleeds with and without aspirin
(7,25). A patient decision aid could
present these data to help patients and
clinicians consider the relative merits
and downsides of aspirin use, as was
donerecentlyforuseofstatintherapyin
patients with diabetes (26).
Summary
While there are insufﬁcient data among
patients with diabetes to conclusively
Table 3—Aspirin-diabetes subgroup interaction analyses
RR* with
diabetes
RR* without
diabetes Pinteraction
Ratio of RRs
pooled across
trials†
Ratio of RRs
pooled within
trials‡
Ratio of RRs
Bayesian analyses§
Mortality 0.97 (0.87–1.08) 0.87 (0.75–1.02) 0.28 1.12 (0.92–1.35) 1.00 (0.53–1.88) 1.16 (0.09–13.79)
Myocardial infarction 0.86 (0.67–1.11) 0.72 (0.55–0.95) 0.36 1.19 (0.82–1.17) 1.02 (0.71–1.47) 1.06 (0.16–6.71)
Ischemic stroke 0.62 (0.31–1.24) 0.89 (0.41–1.94) 0.50 0.70 (0.25–1.97) 0.93 (0.37–2.34) 0.47 (0.01–20.52)
*Random-effects model is used in all meta-analyses. Numbers in parentheses represent 95% CIs. †Ratios of RRs in this method are pooled across randomized
controlled trials and subgroups of randomized controlled trials of patients with diabetes versus without diabetes; then a ratio of pooled estimates is estimated.
Numbers in parentheses represent 95% CIs, which indicate a signiﬁcant interaction if it excludes 1. ‡Ratios of RRs in this method are estimated within each
randomized controlled trial and then pooled. CIs that exclude 1 indicate a signiﬁcant interaction. Numbers in parentheses represent 95% CIs, which indicate a
signiﬁcant interaction if it excludes 1. §Analysis conducted using Bayesian random-effects logistic regression. Numbers in parentheses represent 95% credible
intervals.
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primary prevention of cardiovascular
events, our data suggest, but do not
conﬁrm, that the relative beneﬁt of as-
pirin is similar in patients with and
without diabetes. Additional evidence
from RCTs and individual-patient-data
meta-analyses may help to further clar-
ify this issue.
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